Prospective Grant of Exclusive License: Development of a ME-TARP Based Immunotherapy

本地自动翻译 · 来源原始语言

摘要

This is notice, in accordance with 35 U.S.C. 209 and 37 CFR 404.7, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in the following U.S. Patents and Patent Applications to PDS Biotechnology Corporation ("PDS") located in New Brunswick, New Jersey, USA:

来源原始语言: Federal Register — All Documents打开原始公告 →